The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Demonstrate significant bleed reduction in hemophilia A and B
New facility is part of Aptar Pharma’s global expansion program
Cresemba is the only azole antifungal therapy approved for pediatric patients as young as one affected by these serious, potentially life-threatening infections
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
This acquisition marks Max Healthcare's entry into Lucknow
Subscribe To Our Newsletter & Stay Updated
